{
  "id": "mhgap#referral_36276c21",
  "content": "References\n1. Global burden of disease 2019: mental disorders 8. Dua T, Barbui C, Patel AA, Tablante EC, Thornicroft\n– level 2 cause [website]. Seattle: Institute for G, Saxena S; WHO's mhGAP guideline team.\nHealth Metrics and Evaluations; 2021 (http://www. Discussion of the updated WHO recommendations\nhealthdata.org/results/gbd_summaries/2019/ for mental, neurological, and substance use\nmental-disorders-level-2-cause, accessed 25 disorders. Lancet Psychiatry. 2016;3(11):1008–12\nOctober 2023). (https://doi.org/10.1016/s2215-0366(16)30184-5).\n2. Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, 9. mhGAP intervention guide for mental,\nvan Ommeren M et al. Evidence-based guidelines neurological and substance use disorders in non-\nfor mental, neurological, and substance use specialized health settings: mental health Gap\ndisorders in low- and middle-income countries: Action Programme (mhGAP), version 2.0. Geneva:\nsummary of WHO recommendations. PLoS Med. World Health Organization; 2016 (https://iris.who.\n2011;8(11): e1001122 (https://doi.org/10.1371/ int/handle/10665/250239).\njournal.pmed.1001122).\n10. WHO handbook for guideline development, 2nd\n3. Intersectoral global action plan on epilepsy and edition. Geneva: World Health Organization; 2014\nother neurological disorders 2022–2031. Geneva: (https://iris.who.int/handle/10665/145714).\nWorld Health Organization; 2023 (https://iris.who.\n11. Keynejad RC, Dua T, Barbui C, Thornicroft G. WHO\nint/handle/10665/371495).\nMental Health Gap Action Programme (mhGAP)\n4. Thornicroft G, Sunkel C, Alikhon Aliev A, Baker Intervention guide: a systematic review of",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "referral"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Referral References\n1. Global burden of disease 2019: mental disorders 8. Dua T, Barbui C, Patel AA, Tablante EC, Thornicroft\n– level 2 cause [website]. Seattle: Institute for G, Saxena S; WHO's mhGAP guideline team.\nHealth Metrics and Evaluations; 2021 (http://www. Discussion of the updated WHO recommendations\nhealthdata.org/results/gbd_summaries/2019/ for mental, neurological, and substance use\nmental-disorders-level-2-cause, accessed 25 disorders. Lancet Psychiatry. 2016;3(11):1008–12\nOctober 2023). (https://doi.org/10.1016/s2215-0366(16)30184-5).\n2. Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, 9. mhGAP intervention guide for mental,\nvan Ommeren M et al. Evidence-based guidelines neurological and substance use disorders in non-\nfor mental, neurological, and substance use specialized health settings: mental health Gap\ndisorders in low- and middle-income countries: Action Programme (mhGAP), version 2.0. Geneva:\nsummary of WHO recommendations. PLoS Med. World Health Organization; 2016 (https://iris.who.\n2011;8(11): e1001122 (https://doi.org/10.1371/ int/handle/10665/250239).\njournal.pmed.1001122).\n10. WHO handbook for guideline development, 2nd\n3. Intersectoral global action plan on epilepsy and edition. Geneva: World Health Organization; 2014\nother neurological disorders 2022–2031. Geneva: (https://iris.who.int/handle/10665/145714).\nWorld Health Organization; 2023 (https://iris.who.\n11. Keynejad RC, Dua T, Barbui C, Thornicroft G. WHO\nint/handle/10665/371495).\nMental Health Gap Action Programme (mhGAP)\n4. Thornicroft G, Sunkel C, Alikhon Aliev A, Baker Intervention guide: a systematic review of References\n1. global burden of disease 2019: mental disorders 8."
}